Conjugate Complexes for Immuno-PCR Sensitivity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Immuno-PCR assays face challenges with high background signals due to unspecific binding of sample contents and reagents, which interfere with the detection of minute analyte quantities, leading to a low signal-to-background ratio.

Innovation Solution

The development of conjugate complexes comprising non-nucleic acid receptors, nucleic acid markers, and linker molecules that form supramolecular aggregates, enhancing the sensitivity and signal-to-background ratio through specific binding and amplification of analytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional ELISA or simple antibody-DNA conjugates are used, then the assay is simpler to perform, but the detection sensitivity is insufficient and background signals are high

Engineering Contradiction:
Improvedetection sensitivityVSAvoidconjugate structure complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The conjugate is segmented into distinct functional modules: a capture antibody specific for the analyte, a multivalent linker molecule with multiple binding sites, and a DNA marker. This segmentation allows each component to perform its specific function optimally while reducing non-specific binding, thereby improving detection sensitivity without excessive complexity

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

A multivalent linker molecule serves as an intermediary between the capture antibody and the DNA marker. This linker with multiple binding sites creates a stable conjugate structure that enhances the signal-to-background ratio by ensuring specific binding while maintaining assay simplicity

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If protein A-avidin fusion protein is used to couple DNA to reporter antibody, then coupling is achieved, but unspecific binding to any antibody present occurs causing high background

Engineering Contradiction:
Improvebinding specificityVSAvoidunspecific binding
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The linker molecule is designed with localized binding sites: one end specifically binds to the capture antibody while the other end binds to the DNA marker. This local quality control ensures that binding occurs only at intended locations, preventing unspecific binding to other antibodies and reducing background signals

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The invention converts the potential harm of non-specific binding into a benefit by using a multivalent linker that creates a steric barrier. The multiple binding sites on the linker occupy space around the capture antibody, preventing other antibodies from binding non-specifically while enhancing specific analyte detection

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Measurement precision

If exponential amplification by PCR is used, then detection sensitivity is enhanced, but background signals are also amplified leading to low signal-to-background ratio

Engineering Contradiction:
Improvedetection sensitivityVSAvoidbackground signal
Core Design Contradiction:
Measurement precisionVSObject-generated harmful factors

Solution Approach 1:

The conjugate is pre-assembled with the capture antibody, multivalent linker, and DNA marker before the assay begins. This preliminary action ensures that only specifically bound analytes are attached to DNA markers that will be amplified, preventing amplification of non-specific background signals while maintaining high detection sensitivity

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The multivalent linker acts as an intermediary that couples the capture antibody to the DNA marker in a controlled manner. This intermediary ensures that DNA markers are only introduced through specific analyte binding events, so that subsequent PCR amplification only amplifies specific signals and not background noise

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of these conjugate complexes significantly improves the sensitivity and signal-to-background ratio of Immuno-PCR assays, allowing for more accurate detection of analytes by reducing background noise and enhancing positive signal amplification.

Implementation Method 1

linker molecules adapted to bind non-nucleic acid receptors and nucleic acid markers

Methodology Applied
Scientific EffectMolecular binding: Adsorption

Implementation Method 2

utilizing a streptavidin-biotin system wherein the streptavidin is cross-linked to the antibody

Methodology Applied
Scientific EffectBiotin-streptavidin binding: Adsorption

Implementation Method 3

subsequently utilizing 30 cycles of polymerase chain reaction (PCR) amplification to amplify the reporter DNA sequence

Methodology Applied
Scientific EffectPCR amplification:

Data Source

PatentEP2189539B2Conjugate complexes for analyte detection
Publication Date: 2018.06.13 CHIMERA BIOTEC
  • EP2189539B2 patent drawingFigure 1
  • EP2189539B2 patent drawingFigure 2
  • EP2189539B2 patent drawingFigure 3

AI summary

The present invention relates to novel conjugate complexes for immunoassays as well as kits comprising these conjugate complexes, methods of producing these complexes, and methods of detecting an analyte by use of these complexes. The conjugate complexes of the invention comprise one or more non-nucleic acid receptors capable of specifically binding an analyte, one or more nucleic acid markers comprising a predetermined nucleotide sequence, one or more first linker molecules capable of specifically binding the non-nucleic acid receptor and the nucleic acid marker, and one or more second linker molecules capable of specifically binding the first linker molecules.